Amyris (NASDAQ:AMRS) was downgraded by BidaskClub from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Wednesday.

Other research analysts have also issued reports about the stock. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price target on shares of Amyris in a research note on Monday, April 2nd. Zacks Investment Research raised shares of Amyris from a “hold” rating to a “buy” rating and set a $7.50 price target on the stock in a research note on Wednesday, May 2nd. ValuEngine lowered shares of Amyris from a “buy” rating to a “hold” rating in a research note on Monday, April 2nd. Finally, B. Riley set a $10.00 price target on shares of Amyris and gave the company a “buy” rating in a research note on Sunday, May 20th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the company. Amyris has a consensus rating of “Hold” and a consensus price target of $9.13.

AMRS stock opened at $5.17 on Wednesday. The company has a debt-to-equity ratio of -0.35, a quick ratio of 0.62 and a current ratio of 0.67. Amyris has a 52-week low of $1.86 and a 52-week high of $7.30. The stock has a market cap of $254.90 million, a PE ratio of -1.70 and a beta of 0.15.

Amyris (NASDAQ:AMRS) last issued its quarterly earnings results on Monday, May 14th. The biotechnology company reported ($1.79) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.48) by ($1.31). The company had revenue of $23.00 million for the quarter, compared to analysts’ expectations of $24.12 million. The company’s quarterly revenue was up 77.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.13) earnings per share. sell-side analysts forecast that Amyris will post -1.92 earnings per share for the current fiscal year.

In related news, major shareholder (Mauritius) Pte Ltd Maxwell sold 95,162 shares of the firm’s stock in a transaction dated Monday, May 7th. The shares were sold at an average price of $6.54, for a total value of $622,359.48. The sale was disclosed in a document filed with the SEC, which is available through this link. Company insiders own 21.80% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in the business. Millennium Management LLC acquired a new stake in Amyris in the 1st quarter valued at about $1,643,000. Element Capital Management LLC acquired a new stake in Amyris in the 1st quarter valued at about $227,000. Barclays PLC raised its holdings in Amyris by 30,067.8% in the 1st quarter. Barclays PLC now owns 44,950 shares of the biotechnology company’s stock valued at $300,000 after acquiring an additional 44,801 shares during the last quarter. Tibra Equities Europe Ltd acquired a new stake in Amyris in the 1st quarter valued at about $295,000. Finally, JPMorgan Chase & Co. acquired a new stake in Amyris in the 1st quarter valued at about $655,000. Institutional investors own 23.95% of the company’s stock.

Amyris Company Profile

Amyris, Inc provides various alternatives to a range of petroleum-sourced products worldwide. The company uses its industrial bioscience technology to design microbes primarily yeast, as well as to convert plant-sourced sugars into renewable ingredients. It produces and sells Biofene that converts to squalane, which is used as an emollient in cosmetics and other personal care products; and natural oils and aroma chemicals for the flavors and fragrances market.

Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.